Prognostic impact of early treatment and oxaliplatin discontinuation in patients with stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 adjuvant trials

C Gallois, Q Shi, JP Meyers, T Iveson… - Journal of Clinical …, 2023 - ingentaconnect.com
PURPOSE Oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer
(CC) for 6 months remains a standard in high-risk stage III patients. Data are lacking as to …
被引用次数：14 相关文章

Prognostic impact of early treatment and oxaliplatin discontinuation in patients with stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 adjuvant trials

C Gallois, Q Shi, JP Meyers, T Iveson… - Journal of Clinical …, 2023 - eprints.gla.ac.uk
Purpose: Oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer
(CC) for 6 months remains a standard in high-risk stage III patients. Data are lacking as to …

Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

C Gallois, Q Shi, JP Meyers… - Journal of Clinical …, 2023 - kyushu-u.elsevierpure.com
PURPOSEOxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer
(CC) for 6 months remains a standard in high-risk stage III patients. Data are lacking as to …

Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.

C Gallois, Q Shi, JP Meyers, T Iveson… - Journal of Clinical …, 2022 - europepmc.org
Purpose Oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer
(CC) for 6 months remains a standard in high-risk stage III patients. Data are lacking as to …

Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

C Gallois, Q Shi, JP Meyers, T Iveson… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer
(CC) for 6 months remains a standard in high-risk stage III patients. Data are lacking as to …

Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

C Gallois, Q Shi, JP Meyers… - Journal of Clinical …, 2023 - mayoclinic.elsevierpure.com
PURPOSEOxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer
(CC) for 6 months remains a standard in high-risk stage III patients. Data are lacking as to …

Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

C Gallois, Q Shi, JP Meyers, T Iveson… - Journal of clinical …, 2023 - pubmed.ncbi.nlm.nih.gov
Purpose Oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer
(CC) for 6 months remains a standard in high-risk stage III patients. Data are lacking as to …

Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

C Gallois, Q Shi, JP Meyers… - Journal of Clinical …, 2023 - kyushu-u.pure.elsevier.com
PURPOSEOxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer
(CC) for 6 months remains a standard in high-risk stage III patients. Data are lacking as to …